Female hormone estriol reduces relapse rate by nearly 50 percent, UCLA neurologist reports
A study conducted by Dr. Rhonda Voskuhl, a UCLA neurologist, shows that combining estriol, a female hormone, with Copaxone, a medication currently used to treat multiple sclerosis, reduced the relapse rate of MS by nearly 50 percent with only one year of treatment. (more…)
EAST LANSING, Mich. — Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer. (more…)
COLUMBIA, Mo. – Progestins are used in hormone replacement therapies to counteract the negative effects of estrogen on the uterus and reduce the risk of uterine cancer.
However, evidence in recent studies and clinical trials has demonstrated that progestins increase the risk of breast cancer.
